LAUSR

Key Points Question What is the clinical activity of adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma in the community setting? Findings In this cohort study including 253 patients treated in a community setting, clinical outcomes were broadly consistent with those observed in the CheckMate 274 trial, including for patients who did not receive neoadjuvant chemotherapy. Few adverse events were reported, and the majority of patients were able to complete the standard 12-month scheduled duration of therapy. Meaning These findings support the use of adjuvant nivolumab for patients with muscle-invasive urothelial carcinoma, including those who do not receive neoadjuvant chemotherapy.